Helen Yang

Helen Yang, serves as VP, Head of Clinical Operations and Project Management at Overland Pharmaceuticals.

Prior to Overland, Helen served as Therapeutic Area Lead(Senior Director) at Roche China and led Study Management Teams of Clinical Operations to manage 80+ oncology clinical trials with contributing Chinese patients on global pivotal studies and with joining regional/global trials for China registration purpose including Atezolizumab, Alecensa, Gazyva, Kadcyla, Emicizumab successfully launched in China. Meanwhile, as a core member of Project Team, she joined in Clinical Development Strategy discussion to bring multiple innovative products to China, including Tiragolumab, Entrectinib, Glofitamab, Crovalimab, Polatuzumab, Giredestrant. Before joining Roche, Helen had served at GlaxoSmithKline China for seven years and held multiple clinical operation roles with increasing responsibilities, such as study management, clinical scientist and people management.

Helen brings to Overland over 18 years of clinical research experiences in Oncology(both solid tumor and hematology), Cardiovascular, Endocrinology, etc. Helen received B.S. in pharmacy from Shenyang Pharmaceutical University.